Related Experiment Video
Updated: Jun 19, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Coronary Sinus Narrowing for the Treatment of Patients With Angina and Evidence of Microvascular Dysfunction: A
Maayan Konigstein1, Itamar Loewenstein1, Ophir Freund2
1Department of Cardiology, Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Insights
Coronary sinus Reducer implantation improved microvascular function and quality of life in patients with refractory angina and coronary microvascular dysfunction (CMD). This therapy offers significant relief for challenging angina cases.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Biology
Background:
- Coronary microvascular dysfunction (CMD) causes refractory angina, a challenging clinical condition.
- Coronary sinus Reducer implantation is a recognized therapy for obstructive coronary artery disease (CAD).
- This study investigates the Reducer's efficacy in patients with angina and CMD.
Purpose of the Study:
- To evaluate the impact of Reducer implantation on microvascular function in patients with angina and CMD.
- To assess improvements in angina severity, functional capacity, and quality of life post-implantation.
Main Methods:
- Forty patients with refractory angina, non-obstructive CAD, and CMD underwent Reducer implantation.
- Invasive microvascular function tests (IMR, CFR, RRR, MRR) were performed at baseline and 4 months.
- Angina symptoms (CCS class), functional capacity (6mWT), and quality of life (SAQ) were assessed pre- and post-procedure.
Main Results:
- Significant improvements were observed in IMR, CFR, RRR, and MRR at 4 months post-implantation (p<0.001).
- Canadian Cardiovascular Society (CCS) class improved from III to II.
- Seattle Angina Questionnaire (SAQ) scores and 6-minute walk test (6mWT) distance showed significant improvements (p<0.05).
Conclusions:
- Reducer implantation effectively enhances coronary microvascular function.
- The procedure leads to significant reductions in angina symptoms.
- Patients experience improved functional capacity and quality of life after Reducer implantation.
Background:
Angina caused by coronary microvascular dysfunction (CMD) represents a particularly challenging clinical scenario. Coronary sinus Reducer (Shockwave Medical, Santa Clara, CA) implantation is a safe and effective therapy for patients with refractory angina and obstructive coronary artery disease. We evaluated the efficacy of Reducer implantation in patients with angina and CMD on microvascular function parameters, angina severity, functional capacity, and quality of life (QoL).
Methods:
Patients with refractory angina, nonobstructive coronary artery disease, and evidence of CMD underwent Reducer implantation. Invasive evaluation of microvascular function, including index of microcirculatory resistance, coronary flow reserve, resistive reserve ratio, and microvascular resistance reserve was performed at baseline and 4 months after Reducer implantation. Angina symptoms, functional capacity, and QoL were evaluated using the Canadian Cardiovascular Society class, 6-minute walk test, and Seattle Angina Questionnaire, respectively, at baseline and 4 months after Reducer implantation.
Results:
Forty patients (median age, 68 years [interquartile range (IQR), 59-77 years]; 55% female) were included. At 4 months, median index of microcirculatory resistance decreased (35 [IQR, 25-43] to 17 [IQR, 10-32]; P < 0.001), median coronary flow reserve increased (1.6 [IQR, 1.3-2.0] to 2.8 [IQR, 1.9-3.3]; P < 0.001), median resistive reserve ratio increased (1.9 [IQR, 1.7-2.3] to 2.9 [IQR, 2.0-3.7]; P < 0.001), and median microvascular resistance reserve increased (2.1 [IQR, 1.7-2.5] to 3.3 [IQR, 2.3-4.0]; P < 0.001). Canadian Cardiovascular Society class improved from a median of III to II, alongside significant improvements in 6-minute walk test median distance (300 [IQR, 231-400] to 383 [IQR, 278-452] m; P < 0.001) and all 5 Seattle Angina Questionnaire domains (P < 0.05 for all).
Conclusions:
Reducer implantation significantly improved coronary microvascular function, angina symptoms, functional capacity, and QoL in patients with angina and evidence of microvascular dysfunction.
Clinical Trial Registration:
MOH_2020-04-05_008834 at https://clinicaltrial.health.gov.il/.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease V: Interprofessional Care
Angina IV: Management
Angina I: Introduction
Acute Coronary Syndrome IV: Interprofessional Care
Angina III: Clinical Manifestations and Assessment
